Canton Coin (CC) dropped 16% over seven days, closing near $0.10 on Oct. 20, down from $0.125 on Oct. 13. This decline comes as The Depository Trust Company (DTC) prepares to launch a tokenization service linked to the Canton Network, expected in Q4 2026. The service will allow eligible participants to tokenize securities held at DTC, potentially increasing network activity and CC usage. However, the exact impact on CC's value remains unclear, with the token's decline not directly tied to the service timeline.
Canton Coin's recent 16% decline contrasts with broader cryptocurrency gains on Pluang. As of Oct 21, 2026 08:21 WIB, 44 of 50 major cryptocurrencies rose, while only 5 fell. Among notable movers, COTI increased by 5.12% to Rp203 with a typical hold time of 121 days, SNX rose 4.96% to Rp4,060 with 75% buy order activity, and XTZ gained 4.91% to Rp5,623 despite 67% sell orders.
HUTCHMED has finalized an exclusive license agreement with GSK granting GSK rights to develop and commercialize HMPL-A830, a novel KRAS-EGFR antibody conjugate therapy, outside China, Hong Kong, Macau, and Taiwan. This therapy targets cancers with KR...
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Auna's preliminary Q3 results reveal an 11.7% year-over-year increase in surgeries across Peru, Colombia, and Mexico, driven by higher hospital occupancy and expanded oncology services. Contractual price adjustments also support expectations for EBIT...
Closed-end funds can trade at prices significantly different from their net asset value, creating opportunities for investors to buy at discounts. This article highlights two such funds that provide unique investment exposure and may see their discou...
Actinogen Medical has entered 'database lock' for its XanaMIA Alzheimer's trial, finalizing data collection from 247 patients to analyze the effects of its drug Xanamem. The 36-week trial tested Xanamem's ability to slow Alzheimer's progression by co...
